Fabtech Technologies
- Market cap
- ₹ 529 Cr.
- P/E
- 11x
- P/B
- 1.3x
- 52-week range
- 115.1 – 262.8
- ROE
- 12%
- ROCE
- 14%
- Dividend yield
- 0.5%
- Debt / equity
- 0.17
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- NSE, BSE
About
Fabtech Technologies Ltd. is an India-based transnational pharmaceutical engineering company. It offers end-to-end solutions across the pharmaceutical, biotechnology, and healthcare sectors. The Company focuses on bio clean air, clean water, and process requirements, delivering solutions that span the entire project lifecycle for its customers. It covers various dosage forms, including liquids, solids, and semisolids, across the pharmaceutical value chain. Its turnkey engineering services encompass market analysis, disease profiling, custom equipment design, and the application of advanced technologies to project execution. Its expertise spans across executing a diverse array of projects and solutions, including granulation solutions, isolator containment systems, injectable projects, encapsulation solutions, cleanroom infrastructure, cleanroom systems, cleanroom equipment, heating, ventilation, and air conditioning systems, mechanical, electrical and plumbing and packaging lines.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Fabtech Technologies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)11 against a typical 34.2: cheaper than most peers (1st = cheapest).3rd of 11
- Sales growth+10.2% against a typical +16.4% from a year earlier.7th of 10
- Share price, 3 months−15.8% against a typical −13%.8th of 11
- Size₹ 529.1 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).5th of 11
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB+ | Stable | 15 Oct 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 15 Oct 2025 | Reaffirmed | Crisil BBB+ | — | CRISIL | ₹ 100.25 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 24 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 27 Apr 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 2 Feb 2026 | Financial Results | To consider and approve the financial results for the Quarter ended December 31, 2025 |
| 27 Oct 2025 | Financial Results | FABTECH : 27-Oct-2025 : The Company has informed the Exchange that a Board meeting to be held on October 23, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on October 27, 2025, to consider and approve the financial results for the quarter ended June 30, 2025. |
| 23 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended June 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 59 | 104 | 135 | 68 | 121 | 63 | 159 | 75 |
| Expenses | 54 | 81 | 117 | 74 | 91 | 74 | 136 | 71 |
| Operating Profit | 5 | 23 | 18 | −6 | 30 | −12 | 22 | 4 |
| OPM % | 7.8% | 21.9% | 13.6% | −9.1% | 25.1% | −18.5% | 14% | 5.7% |
| Other Income | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 6 | 24 | 20 | −6 | 31 | −7 | 30 | 5 |
| Tax % | 14.8% | 13% | 24.2% | −1.1% | 10.1% | −15.1% | 26.2% | 19.7% |
| Net Profit | 5 | 20 | 15 | −6 | 28 | −6 | 22 | 4 |
| EPS in Rs | 1.58 | 6.32 | 4.66 | −1.89 | 8.68 | −1.28 | 4.96 | 0.95 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 28%
- 3 Years
- 28%
- TTM
- 14%
- 10 Years
- —
- 5 Years
- 36%
- 3 Years
- 19%
- TTM
- 48%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 20%
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Fabtech Technologies | ₹ 126.00 | ₹ 529 Cr. | 11x | 1.3x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ashwani Kumar Singh
- Chief Executive Officer
- Hemant Mohan Anavkar
- Executive Director
- Neetu Sunil Buchasia
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.